All In MedTech

Device Trial Radar · NCT05829083

DUET Versus Standard Interface for Hypercapnic COPD Patients

Asymmetric (DUET) Versus Conventional Nasal High Flow Interface for Management of Hypercapnic Patients With Mild to Moderate Acute Exacerbation of COPD: A Randomized, Crossover Clinical Trial

Last checked: Nov 19, 2026Latest source record: Sep 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jul 18, 2023

Primary completion

Dec 1, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Larissa University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sotiria General Hospital
First posted
Apr 25, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare the new asymmetric nasal high flow interface with the conventional high flow nasal cannula in patients with COPD exacerbation. The main questions the study aims to answer are: • Does the use of the asymmetric interface lead to: 1. A greater decrease in the patients' carbon dioxide 2. A greater decrease in respiratory rate and less dyspnea 3. Less need for advanced oxygen therapy measures 4. Same tolerance and comfort 5. Lower heart rate and blood pressure Participants will be asked to: Wear the asymmetric and conventional cannulas for 3 hours each with a 30 minute gap in-between. Arterial blood samples and various clinical parameters will be collected throughout the study period. Researchers will compare the effect of asymmetric versus conventional cannulas to answer the aforementioned questions.

Conditions

  • COPD Exacerbation
  • Hypercapnia
  • COPD

Interventions

  • Asymmetric nasal cannula - DUETDevice

    DUET asymmetric nasal high flow interface that fits best to the patients' nostrils (size: one nostril of the patient should be fully occluded) Patients will be crossed-over between the 2 interventions

  • Conventional nasal high flow cannulaDevice

    Well-established conventional nasal high flow cannula (size: medium) Patients will be crossed-over between the 2 interventions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arterial PCO2Time frame: Immediately before and after the application of 3 hours of nasal high flow therapy (3 hours for each cannula type)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sotiria General Hospital

    Athens, Greece · Recruiting

  • University Hospital of Larissa

    Larissa, Greece · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.